Christopher Linthwaite and Gajus Worthington
Fluidigm has appointed Christopher Linthwaite as CEO and member of the board of directors. He succeeds Gajus Worthington, who has stepped down from his positions as CEO and board member. Linthwaite joined Fluidigm as president and chief operating officer earlier this year. He has also served as a senior business executive with Invitrogen, Life Technologies, and Thermo Fisher Scientific.
Molecular Assemblies has appointed Michael Kamdar as CEO and director. Kamdar comes to Molecular Assemblies with more than 25 years of domestic and international pharmaceutical and biotechnology leadership experience, and has held positions at numerous companies, including Agouron Pharmaceuticals, Warner-Lambert, Pfizer, Anadys Pharmaceuticals, VentiRx Pharmaceuticals, Tobira Therapeutics, and Ciclofilin Pharmaceuticals.
Rosetta Genomics has appointed Mark Willig as chief commercial officer. He will be responsible for sales, marketing, and market access for the company's entire diagnostic assay portfolio, and will be reporting to President and CEO Kenneth Berlin. Willig most recently served as senior vice president of sales for CardioDx. Before his time at CardioDx, he served as executive vice president of global sales for Agendia, and has also served in various positions at Thermo Fisher Scientific, PrognostiX, Abbott, and Myriad Genetics.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.